gdc
LeukemiaLymphomaNewsworthy

Celebrating Progress and Sharing Hope: The Leukemia & Lymphoma Society to Host Free Rocky Mountain Blood Cancer Conference for Blood Cancer Patients, Survivors and Caregivers

The Leukemia & Lymphoma Society (LLS) will be hosting its 8th Annual Rocky Mountain Blood Cancer Conference on Saturday, April 7, 2018, at the Hyatt Regency Aurora-Denver Conference Center. LLS Blood Cancer Conferences are free education events for blood cancer patients, survivors, caregivers, family members and healthcare professionals.
Press Releases

DENVER, CO, TUESDAY, MARCH 20, 2018 – The Leukemia & Lymphoma Society® (LLS) will be hosting its 8th Annual Rocky Mountain Blood Cancer Conference on Saturday, April 7, 2018, at the Hyatt Regency Aurora-Denver Conference Center. LLS Blood Cancer Conferences are free education events for blood cancer patients, survivors, caregivers, family members and healthcare professionals.

Local experts from the Colorado Blood Cancer Institute, Kaiser Permanente, Rocky Mountain Cancer Centers and University of Colorado will be updating attendees on the latest in blood cancer research and treatments. Additionally, Caregiver Support will be addressed in the keynote speech by Kimberly Alexander, Principal Consultant at KimCONNECTS.

Conference attendees can look forward to topics like:

  • Car-T Cell Therapies
  • Diagnosis Specific Information
  • Health and Wellness
  • Survivorship and Life After Cancer

“Every year hundreds of patients, caregivers and healthcare providers come together to educate themselves on blood cancer. We are pleased to offer this conference to our community and to see first-hand the impact it has on our residents.” –Rebecca Russell, Executive Director, Rocky Mountain Chapter of The Leukemia & Lymphoma Society

LLS is a catalyst for collaboration within the cancer ecosystem, bringing together industry, government, healthcare providers and academia to develop new and better therapies and accelerate cures. Blood cancer research is the gateway to treatments for many cancers and other serious diseases. LLS is doing more than any health non-profit organization to advance cures and access for blood cancer patients and is having an impact beyond the blood cancers.

The conference enables blood cancer patients and caregivers to network, share, and feel empowered.

For additional information or to register, please visit https://www.eiseverywhere.com/ehome/rmbcc18/641031/ or call (720) 440-8627.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

THE ROCKY MOUNTAIN CHAPTER OF THE LEUKEMIA & LYMPHOMA SOCIETY
720 S. COLORADO BLVD., STE 500-S, DENVER, CO 80246
720-440-8620

Share this:

Recommended For You
LymphomaPatient Stories
Despite No Sex, We Were Never So Married
By Susan Keller
After putting off her neck pain for months, Susan Keller found that she had lymphoma, describing how her loving husband helped her change her attitude and persist through it all.
FDA Approvals, News & UpdatesLymphoma
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
“Today’s approval represents another milestone in the rapidly progressing field of gene therapy,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research.
FDA Approvals, News & UpdatesFollicular LymphomaLymphoma
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA, and is the first targeted, once-daily oral therapy option for marginal-zone or follicular lymphoma.
CLL Monthly MinutesLeukemia
A Look at COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukemia
It is recommended that most patients with CLL receive the COVID-19 vaccine, although each patient should still talk with their healthcare team first.
Last modified: March 27, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country